Brodalumab

Interleukin-17 Receptor A Antagonist — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Brodalumab is a drug in the Interleukin-17 Receptor A Antagonist class catalogued in DrugCentral. It was first approved by the PMDA in 2016. Its mechanism of action is classified as Interleukin 17 Receptor A Antagonists. DrugCentral lists 1 molecular target, including IL17RA|IL17RC. Recorded indications include Ankylosing spondylitis, Erythrodermic psoriasis, Non-radiographic axial spondyloarthritis and Palmoplantar pustulosis.

• Drug class: Interleukin-17 Receptor A Antagonist.
• Mechanism of action: Interleukin 17 Receptor A Antagonists.
• Molecular targets: IL17RA|IL17RC (1 listed in DrugCentral).
• Indications: Ankylosing spondylitis, Erythrodermic psoriasis, Non-radiographic axial spondyloarthritis, Palmoplantar pustulosis and Plaque psoriasis and others.
• ATC code: L04AC12 (Interleukin inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (7)

• Ankylosing spondylitis
• Erythrodermic psoriasis
• Non-radiographic axial spondyloarthritis
• Palmoplantar pustulosis
• Plaque psoriasis
• Psoriatic arthritis
• Pustular psoriasis

Contraindications (1)

• Crohn's disease

Mechanism & targets

• Mechanism of action (MoA): Interleukin 17 Receptor A Antagonists
• Established pharmacologic class: Interleukin-17 Receptor A Antagonist

Molecular targets (1)

Target	Gene	Action	Activity
Interleukin-17 receptor	IL17RA|IL17RC	other	Kd 9.20

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2017-07-17	EMA	—	LEO Pharma A/S
2017-02-15	FDA	—	VALEANT LUXEMBOURG
2016-07-04	PMDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
L04AC12	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Interleukin inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Psoriatic arthropathy	133.6
Psoriasis	117.5
Patient dissatisfaction with treatment	69.0
Therapy interrupted	67.7
Suicidal ideation	63.1
Drug ineffective	62.4
Parakeratosis	60.1
Collagen-vascular disease	56.8
Tinea pedis	55.4
Dermatitis infected	53.3
Disease recurrence	50.1
Arthralgia	49.6

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Brodalumab used for?

DrugCentral lists the following indications for Brodalumab: Ankylosing spondylitis, Erythrodermic psoriasis, Non-radiographic axial spondyloarthritis, Palmoplantar pustulosis, Plaque psoriasis, Psoriatic arthritis and Pustular psoriasis.

How does Brodalumab work?

Brodalumab is classified as Interleukin 17 Receptor A Antagonists; its molecular targets in DrugCentral include IL17RA|IL17RC.

When was Brodalumab first approved?

Brodalumab was first approved by the PMDA in 2016.

What drug class does Brodalumab belong to?

Brodalumab is in the Interleukin-17 Receptor A Antagonist class.

Sources

• DrugCentral drug card 5179 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1742996 — compound record and bioactivity
• DrugBank DB11776 — drug record
• FDA UNII 6ZA31Y954Z — substance identity
• DailyMed: FDA labels for Brodalumab — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.